Convatec announces plans to invest more than $1 billion in R&D facilities – major expansions in the US and UK

- Over $1 billion planned over the next decade to support Convatec’s innovation platform and accelerate growth strategy
- Significant expansion of world-class R&D facilities in Boston, United States, by end 2025
- Major new R&D centre in Manchester, United Kingdom, planned to open in 2027
- Sustained investments in other key locations and manufacturing network

London, UK and Boston, US, 01 October 2025 – Convatec, a global leader in medical products and technologies, today announces plans to invest more than $1 billion over the next decade to accelerate its research and development (R&D) ambitions worldwide. This global, multi-year planned investment marks a significant milestone in Convatec’s mission to deliver breakthrough healthcare solutions and underlines its long-standing commitment to both the United States and the United Kingdom as cornerstones of its global growth strategy.

As part of this plan, Convatec will invest $600m over the next ten years in R&D in the US, underlining the company’s long-term commitment to its most significant market globally. The plans include a significant expansion of its world-class R&D facilities in Boston, United States, by end 2025 – increasing capacity by 50% and further enhancing lab, testing and collaboration space.

In the United Kingdom, Convatec plans to invest £500 million (approximately $650 million), including a new state-of-the-art R&D hub in Manchester, set to open in 2027. The new facility will be one of the largest in Convatec’s global network of Technology & Innovation Centres, with the potential to provide common or shared R&D capabilities and competences across all four of Convatec’s categories: Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. It will also house cutting-edge analytical R&D capabilities, regulatory functions, and digital health innovation, positioning Convatec at the forefront of medical technology development.

Convatec has a proud heritage of innovation that has transformed patient care and improved lives for millions of people worldwide. The company invests over $100 million annually in R&D —approximately 5% of its revenue – which has delivered its strongest ever pipeline of new products designed to address unmet needs in chronic care. In addition to the major US and UK planned investments, Convatec will sustain investment in other key European locations, supporting its global network of Technology & Innovation Centres in Denmark and Slovakia and onsite R&D teams in Mexico and the Dominican Republic, as well as its global manufacturing network.

The plans to enhance Convatec’s R&D footprint in the US and UK follows a comprehensive review of its global growth ambitions. Since 1996, Convatec’s Deeside site has served as a major centre for R&D alongside its manufacturing operations. The company has now identified Manchester as the ideal location for its new, enlarged UK facility, given its vibrant life sciences ecosystem, which includes leading universities, hospitals, and research institutions. In the US, the expansion of the Boston site will further strengthen Convatec’s innovation leadership and support the company’s largest market.

The new Manchester R&D hub will be home for around 200 highly skilled colleagues, largely transferring from Convatec’s existing Deeside R&D site, with plans for further growth in the years ahead. Convatec’s manufacturing site in Deeside, North Wales, will remain a cornerstone of its global operations and is unaffected by this change, with around 400 employees continuing to be based there after the move completes in 2027.

Jonny Mason, Interim Chief Executive Officer at Convatec, said:
“Today’s announcement marks an exciting moment in Convatec’s commitment to pioneering trusted medical solutions to improve the lives we touch. Our plans to invest more than $1 billion – anchored by major expansion plans in both the United States and the United Kingdom – demonstrates our unwavering commitment to advancing healthcare innovation for people living with chronic conditions around the world.”

Dr. Divakar Ramakrishnan, Chief Technology Officer and Head of Research & Development at Convatec, said: “The significant expansion of our R&D capabilities in Boston and plans to establish a new flagship centre in Manchester are investments in the talent, technology, and infrastructure needed to accelerate innovation in pioneering trusted chronic care solutions. They reinforce our belief in the strength of the US and UK life sciences sectors and position Convatec at the forefront of medical technology innovation for years to come.”

The US expansion is expected to be completed by end 2025, and the new Manchester hub is expected to be operational by 2027, with a phased transition to ensure minimal disruption to ongoing projects and close collaboration with Convatec’s wider global network of Technology & Innovation Centres. When fully operational, these flagship sites in Boston and Manchester will be at the heart of Convatec’s global innovation network, which includes major sites in the UK, US, Denmark, and Slovakia. Both sites will play crucial roles in Convatec’s R&D strategy along with other centres to drive innovation across Convatec’s business worldwide.

Notes to editors

UK market environment
It is vital that companies like Convatec can continue to invest in pioneering medical solutions in the UK. Convatec sees the UK as an attractive destination for life sciences, with a deep talent pool, strong research base, and supportive environment for innovation. Convatec’s plans, subject to government support, reflect our confidence in the UK’s future as a global hub and in the role Convatec can play in delivering solutions to our customers. It is critical that UK Government policy, legislation, reimbursement decisions and initiatives enable companies like Convatec – with UK manufacturing, R&D and other investments in the UK – to serve the best interests of patients, protect patient and provider choice, and deliver value for taxpayers.

Bruntwood SciTech
Bruntwood SciTech - a joint venture between Bruntwood, Legal & General and Greater Manchester Pension Fund - is creating a network of city-wide innovation ecosystems; connecting the UK’s cities, regions and communities of like-minded businesses through extensive opportunities for collaboration and access to our public, private, academic and clinical partner network. Bruntwood SciTech provides direct connections to highly skilled talent, funding, universities, the NHS and mentorship. Citylabs 4.0 is Bruntwood SciTech’s new £42m, 125,000 sq ft world-class development of lab and office space. Located on the Manchester University NHS Foundation Trust, one of the UK’s largest NHS Trusts, the health innovation campus is home to a community of diagnostic, MedTech, digital health and genomics businesses driving the future of healthcare. For further information, visit their website here.

Contacts
Media: mediarelations@convatec.com
Analysts & investors: ir@convatec.com 

About Convatec 
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com